School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1211 Geneva, Switzerland.
School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1211 Geneva, Switzerland.
Drug Discov Today. 2018 Oct;23(10):1761-1775. doi: 10.1016/j.drudis.2018.05.023. Epub 2018 May 21.
Osteoarthritis (OA) is the most common degenerative disease of the joint. Despite many reports and numerous clinical trials, OA is not entirely understood, and there is no effective treatment available for this disease. To satisfy this unmet medical need, drug delivery systems (DDSs) containing disease-modifying OA drugs (DMOADs) for intra-articular (IA) administration are required to improve the health of OA patients. DDSs should provide controlled and/or sustained drug release, enabling long-term treatment with a reduced number of injections. This paper reviews the role and interaction among different tissues involved in OA and summarizes recent clinical trials and research on DDSs, focusing on small-molecule delivery. To achieve an ideal treatment, various key criteria have been identified to design and develop an IA DDS matching the clinical needs.
骨关节炎（OA）是最常见的关节退行性疾病。尽管有许多报道和大量的临床试验，但 OA 仍未被完全了解，也没有针对这种疾病的有效治疗方法。为了满足这一未满足的医疗需求，需要含有治疗骨关节炎的药物（DMOAD）的药物输送系统（DDS）用于关节内（IA）给药，以改善 OA 患者的健康状况。DDS 应提供控制和/或持续的药物释放，使患者能够通过减少注射次数来进行长期治疗。本文综述了不同组织在 OA 中的作用和相互作用，并总结了最近关于 DDS 的临床试验和研究，重点是小分子的递药。为了实现理想的治疗效果，已经确定了各种关键标准，用于设计和开发符合临床需求的 IA DDS。
